IVBXF (IVBXF) Stock Price & Analysis
IVBXF (IVBXF) rose 5.08% to USD 10.76 as of June 9, 2026 at 23:55 UTC, according to Nexqual real-time market data.
IVBXF last closed at USD 10.24; the session ranged USD 10.76–10.76 on volume of 600 shares. Market capitalization is $18.66B, with a 52-week range of USD 9.1–15.12 (PNK). Source: Nexqual, June 9, 2026 at 23:55 UTC.
Key Statistics (as of June 9, 2026 at 23:55 UTC)
| Price | USD 10.76 |
|---|---|
| Change | ▲ 5.08% (up) |
| Previous Close | USD 10.24 |
| Open | USD 10.76 |
| Day Range | USD 10.76 – 10.76 |
| 52-Week Range | USD 9.1 – 15.12 |
| Volume | 600 shares |
| Market Cap | $18.66B |
| Exchange | PNK |
Technical Analysis (IVBXF)
Nexqual's technical model rates IVBXF "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:55 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.35 (neutral) |
| vs SMA50 | Above (USD 10.68) |
| MACD | -0.29 (negative) |
Analyst Ratings (IVBXF)
Wall Street analysts rate IVBXF "None", per Nexqual as of June 9, 2026 at 23:55 UTC.
| Consensus Rating | None |
|---|
Earnings (IVBXF)
| Next Earnings Date | 2026-03-26 |
|---|
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Financials & Fundamentals (IVBXF)
| Total Revenue | $13.04B |
|---|---|
| Revenue Growth (YoY) | +29.60% |
| Gross Margin | +76.66% |
| Operating Margin | -0.56% |
| Profit Margin | +6.24% |
| ROE | +5.01% |
| Debt / Equity | 14.55 |
| Current Ratio | 2.63 |
| Total Cash | $18.23B |
| Total Debt | $2.82B |
| Free Cash Flow | $3.23B |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Financial Health Score (IVBXF)
Nexqual rates IVBXF's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:55 UTC.
| Growth | Strong — Revenue +38% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 77%, operating -1% |
| Balance Sheet | Strong — $18.2B cash vs $2.82B debt, net cash position |
| Cash Flow | Strong — FCF $3.23B, 25% margin |
| Efficiency | Mixed — ROE 5%, ROA 1.6% |
Ownership (IVBXF)
| Insider Ownership | +6.26% |
|---|---|
| Institutional Ownership | +57.18% |
| Shares Outstanding | 1.73B |
| Float | 1.61B |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Leadership (IVBXF)
IVBXF is led by De-Chao Yu (age 61), Co-Founder, Chairman & CEO, per Nexqual as of June 9, 2026 at 23:55 UTC.
| Co-Founder, Chairman & CEO | De-Chao Yu (age 61) |
|---|---|
| Executive Director & Fund Managing Partner | Hao Xi Ede (age 66) |
| Chief Commercial Officer, General Manager & Executive Director | Qian Zhang (age 38) |
| Chief Financial Officer | Fei You (age 46) |
| Chief Operating Officer | Kaisong Zhou |
Major Backers & Investors (IVBXF)
Notable institutional backers of IVBXF include EuroPacific Growth Fund-EUPAC Fund, New World Fund Inc, SmallCap World Fund Inc, according to Nexqual as of June 9, 2026 at 23:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| EuroPacific Growth Fund-EUPAC Fund | 1.16% |
| New World Fund Inc | 0.79% |
| SmallCap World Fund Inc | 0.4% |
| Fidelity | 0.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.79% |
| BlackRock | 1.36% |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WXIBF | Wuxi Biologics (Cayman) Inc | USD 4.4 | ▲ 0% |
| WXXWY | Wuxi Biologics (Cayman) Inc | USD 7.6 | ▼ 7.09% |
| UCBJY | UCB S.A. | USD 151.74 | ▲ 1.47% |
| TLPPF | Telix Pharmaceutical Ltd. | USD 9.5 | ▲ 0% |
| GNMSF | Genmab A/S | USD 249 | ▼ 0.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:55 UTC. This page is informational and not investment advice.